Filing Details
- Accession Number:
- 0001104659-23-010733
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-03 18:17:05
- Reporting Period:
- 2023-01-20
- Accepted Time:
- 2023-02-03 18:17:05
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1657312 | Verona Pharma Plc | VRNA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1836883 | A. Kathleen Rickard | 3 More London Riverside London X0 SE1 2RE | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2023-01-20 | 105,000 | $0.00 | 3,196,024 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2023-02-01 | 89,960 | $2.56 | 3,106,064 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2023-02-02 | 28,752 | $2.53 | 3,077,312 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Restricted Share Units | Disposition | 2023-01-20 | 105,000 | $0.00 | 105,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,000 | 2029-03-29 | No | 4 | M | Direct |
Footnotes
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- These sales were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.
- The price reported represents the sale price of the ADSs divided by eight (8).
- The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2022.
- The price reported represents a weighted average sale price of the ADSs divided by eight (8). These shares were sold in multiple transactions at prices ranging from $2.4738 to $2.6063, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Consists of (i) 1,950,184 Ordinary Shares underlying RSUs (which are represented by 243,773 ADSs); and (ii) 1,127,128 Ordinary Shares underlying 140,891 ADSs.
- Each Restricted Share Unit represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer) subject to certain time- and performance-based vesting criteria.
Billionaire Hedge Funds
